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INTRODUCTION
Asthma is a chronic respiratory disease mediated by a wide 
range of environmental and genetic factors.1 It is characterized 
by coughing, wheezing, bronchoconstriction, airway hyperre-
sponsiveness, or airway remodelling. Due to its multifactorial 
nature, several studies have attempted to elucidate the genetic 
background of asthma pathogenesis.2-6
The Hippo pathway is highly conserved from Drosophila me-
lanogaster to mammals and regulates organ size through pro-
moting apoptosis and inhibiting cell proliferation in the embry-
onic stages of development.7 It is still not exactly known how 
the pathway is regulated by organ size; however, it has been 
proposed that FRMD6 (also known as Willin) influences the ac-
tivity of the Hippo pathway by turning on the central kinase 
cascade.8 The members of this signaling cascade, MST1/2 and 
LATS1/2 with scaffold proteins SAV1 and MOB1, respectively, 
phosphorylate one another to inhibit YAP1/TAZ, the main ef-
fectors of the pathway.9 YAP1 and TAZ are transcriptional co-
activators that bind to transcription factors, when active, such 
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as TEAD, SMAD, or TP73, to regulate the expression of anti-
apoptotic (e.g., BIRC5), or apoptotic genes.10-12 Recently, it has 
been shown that YAP1 is also widely expressed in respiratory 
epithelial cells of the embryonic and mature lung and that Hip-
po/YAP1 signalling regulates epithelial cell proliferation and 
differentiation, and play an important role in embryonic lung 
maturation and postnatal airway homeostasis.13 Furthermore, 
in mice it has been demonstrated that YAP is dynamically regu-
lated during regeneration of the airway epithelium following 
lung injury, suggesting a possible role of Hippo/YAP1 signaling 
in the pathogenesis of acute and chronic lung diseases.14
Previously, it has been found that genetic variations in 
FRMD6, an upstream activator of the Hippo pathway, were as-
sociated with asthma.15 Furthermore, genetic variations in the 
BIRC5 gene (also known as survivin), which is one of the target 
genes of YAP1 (Fig. 1), influenced the susceptibility to the dis-
ease.16 In addition, the sputum mRNA level of FRMD6 was sig-
nificantly lower, while that of BIRC5 was higher in asthmatic pa-
tients than in healthy controls.15,16
Based on these data, we hypothesized that the Hippo/YAP1 
pathway may play a role in the pathogenesis of asthma. The 
main aim of our study was to investigate the members of the 
Hippo pathway and compare their gene expressions in the in-
duced sputum of asthmatic patients and healthy controls. 
Moreover, we also determined whether genetic variations in 
the YAP1 gene can influence the susceptibility of asthma or 
subgroups of asthma.
To evaluate the role of the Hippo/YAP1 pathway and one of its 
target genes, BIRC5, as a system in asthma and allergy, we also 
analyzed our data with the BN-BMLA method, in order to pro-
vide more information on the relationship between genetic 
variations in the YAP1, FRMD6, and BIRC5 genes, asthma sus-
ceptibility, as well as other types of variables, e.g., allergy, eosin-
ophils, immunoglobulin E (IgE), and asthma phenotypes.
MATERIALS AND METHODS
Subjects
Gene expression analysis was carried out using the induced 
sputum of 18 asthmatic patients and 10 healthy controls. All the 
study participants completed a detailed, pre-edited question-
naire. The recent Global Initiative for Asthma (GINA) guide-
lines (www.ginasthma.org) were used to diagnose asthma by a 
respiratory medicine specialist. The evaluation of asthma se-
verity was done at the time of acquisition of induced sputum 
samples from the patients based on patient history, including 
number of exacerbations per year, lung function test results, 
medical treatment applied, and response to medication. The 
asthmatic patients were divided into 4 severity groups; howev-
er, Global Initiative for Asthma 1, 2 (mild) and GINA 3, 4 (mod-
erate-severe) were aggregated because of the small number of 
patients. Of the 18 asthmatic patients, 14 regularly used inhaled 
corticosteroids (ICS): <500 μg/day beclomethasone dipropio-
nate (BDP) or equivalent (n=5), 500-1,000 μg/day BDP or 
equivalent (n=7), and >1,000 μg/day BDP or equivalent (n=2); 
while 4 were considered steroid naive. Controls were healthy 
volunteers with no previous history of asthma or any airway 
conditions. All subjects participated in a lung function test 
Fig. 1. Examples of signals and pathways regulating YAP1 activity.25-28
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(PDD-301/S; Piston Inc., Budapest, Hungary) and were as-
sessed for fractional exhaled nitric oxide (FENO) levels (NIOX 
MINO; Aerocrine, Solna, Sweden). All the healthy patients had 
a normal lung function and had no respiratory tract infection 4 
weeks prior to the analysis. A skin prick test was also performed 
for common allergens in order to test the presence of atopy, 
which is a genetic predisposition to develop allergic rhinitis, 
atopic dermatitis, and/or asthma. The participants’ sex, age, 
smoking habits, and allergic statuses were compared between 
cases and controls, and between severity groups, but no statisti-
cal significance was found.16 Table 1 shows a summary of this 
study population.
The genotyping analysis included 1,233 unrelated individuals, 
out of which 522 were asthmatic children (mean age±standard 
deviation [SD], 10.20±5.31 years; 218 males and 194 females), 
and 711 healthy controls (mean age±SD, 14.00±11.22; 429 
males and 282 females). The patients were all Hungarian (Cau-
casian), from which about 5%, based on state population data, 
were of Gypsy origin. Asthma was diagnosed based on the 
GINA guidelines as previously described. Atopy was identified 
by a positive skin prick test and/or positive total or specific se-
rum IgE levels. The total and specific serum IgE levels were test-
ed with the 3gAllergy blood tests in the Immulite 2000 Immu-
noassay system (Siemens Healthcare Diagnostics, Tarrytown, 
NY, USA). The resulting serum IgE levels were either normal or 
high based on age-specific ranges (kU/L).
Different types of asthma were defined in patients, except for 
131 subjects (25%), where not enough information was available 
on asthma phenotypes; hence altogether, 391 asthmatic chil-
dren were involved in the phenotype analysis. Asthma was di-
vided into allergic and non-allergic asthma subtypes. If asthma 
was not provoked by allergens but allergy was also present, the 
allergy types were marked. In allergic patients, depending on 
the types and quantities of allergens, subgroups of indoor, out-
door, or inhalative allergic phenotypes have been created. If 
asthma exacerbation was provoked by exercise in the medical 
history of the patients, asthma was categorized as exercise-in-
duced one. If the onset of asthma or asthma exacerbations have 
been associated with an infection-related acute respiratory ill-
ness, asthma was classified as viral-induced one. Non-atopic 
patients with viral-induced asthma phenotype composed the 
non-allergic asthma subgroup.17 Indoor allergens included dust 
mites, mold, pet dander, and cockroaches, whereas outdoor al-
lergens consisted of different types of pollen. Eosinophil cell 
counts from blood were measured with the Coulter AXM ana-
lyzer, of which the normal relative range was between 1%-6%, 
and the normal range of absolute eosinophil count was between 
50-200/μL. The patients had no change of therapy before the 
blood samples were taken. Neither did they have exacerbations 
or respiratory infections for at least 4 weeks prior to the blood 
test. The detailed characteristics of the asthmatic patients partic-
Table 1. Detailed characteristics of subjects participating in sputum analysis






Age±SD (yr) 43.7±16.7 29.3±4.6
Sex (Male/female) 10/8 5/4
Asthma severity:
   Mild (GINA 1, 2) 11 -
   Moderate-to-severe (GINA 3, 4) 7 -
Sputum eosinophil (%) 13.1±12.4 0±0
Sputum neutrophil (%) 20.3±17.9 18.1±9.3
Sputum macrophage (%) 59.8±21.0 74.8±8.2
Sputum bronchial epithelial cell (%) 1.2±1.6 7.1±5.7
ICS dose±SD (μg) 594.4±527.4 -
FENO level±SD (ppb) 22.6±12.5 NA
FEV1 level±SD (L) 2.3±0.7 -
SD, standard deviation; GINA, Global Initiative for Asthma; ICS, inhaled cortico-
steroid; FENO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 
1 second; NA, not available.
Table 2. Detailed characteristics of asthmatic patients participating in SNP 
analysis
Clinical and biological characteristics Asthmatic patients (n=522)
Age±SD (yr) 10.2±5.3
Sex (Male/female) 328/194
Asthma phenotypes/sensitization status of  
subjects, yes/no*:
n=486
   Exercise-induced 155/233
   Viral-induced 181/208
   Allergic asthma 56/82
   Inhalative allergy 298/99
   Outdoor allergy 240/149
   Indoor allergy 225/164
   Comorbidity rhinitis 217/173
   Comorbidity conjunctivitis 120/270
GINA status*:
   No. of patients in GINA 1 97
   No. of patients in GINA 2 241
   No. of patients in GINA 3 48
   No. of patients in GINA 4 96
Absolute eosinophil count±SD (No./μL) 300±300




No. of patients with normal or high IgE level  
(normal/high)
88/182
SNP, single nucleotide polymorphism; SD, standard deviation; GINA, Global Ini-
tiative for Asthma; IgE, immunoglobulin E.
*Data are available on a limited data set only. Normal absolute eosinophil 
count is <200/μL and high absolute eosinophil count is ≥200/μL. Normal IgE 
level is <200 kU/L, high IgE level is ≥200 kU/L.
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ipating in the gene association study are presented in Table 2.
The control children were from the Orthopaedic Department 
in Budai Children’s Hospital or from the Urological Depart-
ment from Heim Pál Hospital, both in Budapest. The controls 
had no symptoms of asthma or any airway conditions, nor any 
need for medication.
Written informed consents were signed by all patients or by 
their parent/guardian. The study was done according to the 
Declaration of Helsinki and approved by the Ethics Committee 
of the Hungarian Medical Research Council.
Sputum induction
Induced sputum was used for gene expression assays and 
Western blot analysis. Sputum samples were taken and pre-
pared as previously described by Ungvári et al.16
RNA isolation and cDNA production
RNA was isolated successfully from the induced sputum sam-
ples of 18 patients and 10 control subjects with the Qiagen Mini 
RNeasy Kit according to the manufacturer’s instructions (Qia-
gen, Germantown, MD, USA). The cDNA used in the gene ex-
pression analysis was produced with the High Capacity cDNA 
Reverse Transcription Kit from Thermo Fisher Scientific (Ther-
mo Fisher Scientific, Waltham, MA, USA).
Gene expression analysis
Real-time quantitative polymerase chain reaction (PCR) was 
performed on LATS1, LATS2, MST1, MST2, SAV1, YAP1, TAZ, 
and β-actin genes using the 7900HT Fast Real-Time PCR Sys-
tem (Thermo Fisher Scientific) in which β-actin was used as an 
endogenous control, and all results were normalized to it.
DNA isolation and genotyping
Genomic DNA was isolated from the whole blood samples of 
1,233 individuals using the QIAamp blood DNA midi kit (Qia-
gen) or the iPrep PureLink gDNA Blood kit on the iPrep Purifi-
cation Instrument (Invitrogen, Carslbad, CA, USA). KBiosci-
ences Competitive Allele-Specific PCR (KASP) version 4.0 ge-
notyping assays were used (LGC Genomics, Berlin, Germany) 
to genotype 14 single nucleotide polymorphisms (SNPs) on the 
YAP1 gene (Table 3) according to the manufacturer’s instruc-
tions. PCR reactions were carried out using the 7900HT Fast Re-
al-Time PCR System (Thermo Fisher Scientific).
Western blot analysis
Western blot analysis was carried out with human induced 
sputum samples. After sample preparation, cells were lysed in 
RIPA lysis and extraction buffer (Thermo Fisher Scientific) sup-
plied with Halt protease inhibitor (Thermo Fisher Scientific) at 
1x final concentration and centrifuged at 14,000×g at 4°C for 15 
minutes. Total protein content was determined by the Pierce 
BCA protein assay kit (Thermo Fisher Scientific) according to 
the manufacturer’s instructions. Samples were loaded on 4%-
20% Tris-glycine precast gels (Thermo Fisher Scientific) and 
then blotted onto the Immun-Blot PVDF membrane (Bio-Rad 
Laboratories, Hercules, CA, USA). After blocking, the following 
antibodies were used. The primary antibodies were anti-FR-
MD6, anti-YAP1, and anti-GAPDH (Abcam, Cambridge, UK). 
The secondary antibodies were polyclonal donkey anti-rabbit 
IgG HRP (Abcam) and polyclonal goat anti-mouse immuno-
globulins HRP (Dako, Glostrup, Denmark). The membrane was 
treated with Pierce ECL plus substrate (Thermo Fisher Scientif-
ic) according to the manufacturer’s instructions, and bands were 
Table 3. Description of selected SNPs and results of the genotyping
SNP Position according to the NCBI Genome Build 38 Function
Alleles on the 
forward strand MAF in cases MAF in controls
HWE in controls 
(P value)
rs1820453 chr11:102109604 Promoter A/C 0.45 0.47 1.00
rs7106388 chr11:102110546 5'UTR C/T 0.45 0.48 0.82
rs10895257 chr11:102115913 Intron A/G 0.22 0.24 0.75
rs1426398 chr11:102117330 Intron C/T 0.45 0.46 1.00
rs11225138 chr11:102123167 Intron C/G 0.10 0.09 0.15
rs1426394 chr11:102149503 Intron A/G 0.29 0.31 0.05
rs948737 chr11:102158098 Intron C/T 0.33 0.36 0.08
rs1942683 chr11:102173916 Intron A/G 0.40 0.42 0.69
rs11225161 chr11:102199763 Intron C/T 0.12 0.11 0.35
rs1894116 chr11:102199908 Intron C/T 0.12 0.12 1.00
rs11225166 chr11:102219736 Intron C/G 0.11 0.12 0.71
rs8504 chr11:102232869 3'UTR A/G 0.42 0.44 0.49
rs2846836 chr11:102234942 Downstream C/T 0.44 0.46 1.00
rs7115540 chr11:102267059 Downstream A/G 0.36 0.35 0.32
SNP, single nucleotide polymorphism; NCBI, National Center for Biotechnology Information; MAF, minor allele frequency; HWE, Hardy-Weinberg equilibrium.
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visualized on a standard X-ray film (Kodak, Rochester, NY, USA).
Frequentist statistical analysis
For sputum analysis, normalized gene-expression levels were 
compared by the Mann-Whitney U or Kruskal-Wallis test as ap-
propriate. Contingency tables were analyzed by Fisher’s exact 
test. Correlation studies were performed by the Spearman non-
parametric test. Differences were considered significant if 
P<0.05. Allele frequencies between the groups of case and con-
trol subjects were estimated by allele counting and tested for 
deviation from Hardy-Weinberg equilibrium (HWE) by the 
software program DeFinetti (https://ihg.gsf.de/cgi-bin/hw/
hwa1.pl). For the significant deviation threshold, we used a P 
value of <0.05.
SNP data were analyzed using SPSS software version 22 (SPSS 
Inc., Chicago, IL, USA). Logistic regression analyses adjusted 
for age and gender were used to evaluate the association be-
tween YAP1 genotypes and asthma, its intermediate pheno-
types, the discretized (normal/high) serum IgE and discretized 
(normal/high) eosinophil levels (see at Subjects) or different 
phenotypes. Additionally, multinomial logistic regression ad-
justed for age and gender was used for the analysis of YAP1 
SNPs and GINA statuses. Confidence intervals (CIs) were cal-
culated at the 95% level. Multiple comparisons were corrected 
for using the Benjamini-Hochberg correction, and a new signif-
icance level of P=0.004 with the false discovery rate (FDR) 
<6.5% was estimated. Haplotype analysis was carried out with 
the Haploview 4.2 program (Broad Institute of MIT, Cambridge, 
MA, USA). Odds ratios (ORs) for haplotypes were counted by 
VassarStats software (http://vassarstats.net/index.html).
Bayesian statistical analysis
Earlier, we have developed an alternative, a systems biological 
statistical method, named Bayesian network based Bayesian 
multilevel analysis of relevance (BN-BMLA). Bayesian networks 
offer a rich language for genetic association studies, because 
they exhaustively and exactly represent strongly relevant vari-
ables and their interactions through the Markov Blanket Set 
and Markov Blanket Graph features and they are able to evalu-
ate multiple targets. Furthermore, this Bayesian global rele-
vance analysis method provides posterior probabilities, which 
are direct statements about hypotheses; thus, it can also be 
used to construct probabilistic data analytic knowledge bases 
in genetic association studies to support complex querying, off-
line meta-analysis, and fusion with background knowledge.18-21
We have previously described the BN-BMLA method in de-
tail,15,22-24 so that the following only briefly summarizes this ap-
proach.
A Bayesian network is a directed acyclic graph (DAG) that aids 
the discovery of various dependency relations between ran-
dom variables by representing their joint probability distribu-
tion. A node in the network represents a variable, and edges 
connecting 2 nodes represent direct dependency between 
those variables. To find the dependence relations of the vari-
ables, a DAG that best describes the dataset must be found. In 
most cases, there are many DAGs with non-negligible posteri-
ors, but certain structural features may be extracted accurately. 
Such a feature is based on the concept of strong relevance of a 
single variable or a set of variables. Bayesian learning allows the 
evaluation of the strength of the data indicating the presence of 
a certain feature by evaluating its a posteriori probability.
The a posteriori probability can be calculated for strongly rele-
vant variable sets with regard to a target variable. The strongly 
relevant variables have direct impacts on the target. The a pos-
teriori probability of the strong relevance is between 0 and 1, 
where 1 means that the target (e.g., phenotypes of asthma) 
most certainly has a dependency relationship with a predictor 
(e.g., SNP), on the other hand 0 means that there is no such re-
lationship. Posterior probabilities of strong relevance greater 
than or equal to 0.5 are regarded as relevant, and above 0.75 as 
convincing.18-21
In the present study, 29 SNP in the YAP1, FRMD6, and BIRC5 
genes (genotyped with the same methods and on the same 
populations;15,16 Supplementary Table S1) and the characteris-




Gene expression in induced sputum
In the induced sputum of 18 asthmatic patients and 10 con-
trol subjects, we measured the gene expression level of 7 mem-
bers of the Hippo/YAP1 pathway. The expression of all genes 
was detected in both cases and controls. The mean gene ex-
pression level of YAP1 was slightly lower in the asthmatic pa-
tients than in the control subjects (P=0.032, Fig. 2A). No other 
differences were detected in this respect. We investigated 
whether within the asthma group there were differences in 
gene expression between the subgroups of patients defined by 
GINA status, but no significant differences were found.
During the correlation studies, we found a significant and 
positive correlation between YAP1 mRNA levels and sputum 
bronchial epithelial cells (r=0.575, P=0.003; Fig. 2B). There was 
a significant and negative correlation between TAZ mRNA and 
sputum neutrophils (r=-0.509, P=0.009), and STK4 showed a 
significant and positive correlation with sputum eosinophils 
(r=0.425, P=0.034). There was no significant correlation of 
YAP1, TAZ, LATS1, LATS2, SAV1, STK3, or STK4 gene expres-
sion with other cellular components, asthma severity, age, gen-
der, airway inflammation, or ICS dose.
SNP association study results
We examined whether any of the SNPs in the YAP1 gene in-
fluence the susceptibility of asthma or different phenotypes. 
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The statistically significant genotyping results are summarized 
in Table 4. There was no significant association of the SNPs with 
asthma susceptibility, allergic status, inhalative, outdoor, in-
door allergies, allergic and non-allergic asthma, comorbidities 
of rhinitis and conjunctivitis or serum IgE and eosinophil lev-
els. However, SNP rs2846836 was significantly associated with 
exercise-induced asthma (OR=2.1 [1.3-3.4], P=0.004, pow-
er=0.83; Table 4 and Supplementary Fig. S1A). Additionally, 
the distribution of genotypes of SNP rs11225138 showed a sig-
nificant difference between GINA 1-2 and GINA 3-4 statuses in 
a dominant model (OR=2.8 [1.4-5.6], P=0.003, power=0.83; 
Table 4 and Supplementary Fig. S1B).
In order to find more evidence for the associations, we also 
conducted haplotype analyses. We found a significant differ-
ence between patients of GINA 2 and GINA 3 when we com-
pared the frequencies of a haplotype formed by the rare alleles 
of SNPs rs1426398 and rs11225138, where the frequency of TC 
haplotype was more prevalent in GINA 3 than in GINA 2 (28% 
vs 8%, P=10-7). Furthermore, the CA haplotype from SNPs 
rs11225138 and rs1426394, also showed a significant difference 
when patients with GINA 3 were compared to GINA 2 asthmat-
ics (26% vs 7%, P=10-7). When we included more than 2 SNPs 
in the analysis, additional associations were found. Corre-
sponding results are shown in Supplementary Table S2 and 
Supplementary Fig. S2.
Western blot analysis of induced sputum
Western blots were carried out on the proteins of the Hippo/
YAP1 pathway whose genetic variations showed significant as-
sociations with asthma or phenotypes. Earlier, we found a 
strong significant association between a genetic variation in the 
FRMD6 gene and asthma (P<0.001, Supplementary Table 
S1),15 and in the present study genetic variations and haplo-
types in the YAP1 gene was associated with different pheno-
types of asthma.
The signal for the FRMD6 protein could be detected in all 
sputum samples from both asthmatic patients and control sub-
jects.  Interestingly, although the YAP1 protein was not detected 
in the sputum samples of the healthy controls, it was seen in 
the sputum samples of the mild asthmatics (GINA 1, 2) and was 
absent in the sputum of severe (GINA 3, 4) asthmatics (Supple-
mentary Fig. S3).
BN-BMLA
Based on the genotyping results of 29 SNPs in YAP1, FRMD6, 
and BIRC5 genes, the laboratory data and characteristics of the 
asthmatic patients detailed in Table 2, the posterior probabili-
ties of relevance between the variables with respect to target 
Fig. 2. (A) YAP1 mRNA levels in the induced sputum of asthmatic patients (n=18) and controls (n=10). (B) Relationship between YAP1 mRNA and bronchial epitheli-
al cell levels. The mRNA levels were normalized and expressed according to the delta delta Ct method. The Mann-Whitney U test (A) and Spearmann’s non-para-
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Table 4. Significant results of the association analysis of YAP1 SNPs with asthma phenotypes 
Phenotype SNP Model Alleles (1/2) Phenotype
Genotypes
No. P value OR (95% CI)11 (%) 12 (%) 22 (%)
Exercise-induced asthma rs2846836 Additive C/T Present 37 (27) 77 (57) 22 (16) 136 0.004 2.1 (1.3-3.4)
Absent 80 (38) 80 (38) 51 (24) 211
GINA 1, 2 vs 3, 4 rs11225138 Dominant G/C GINA 1, 2 261 (83) 53 (17) - 314 0.003 2.8 (1.4-5.6)
GINA 3, 4 87 (70) 37 (30) - 124
In case of rs2846836 genotypes 11, 12, and 22 are TT, CT, and CC, respectively. In case of rs11225138 genotypes 11, 12, and 22 are GG, GC, and CC, respectively.
SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval; GINA, Global Initiative for Asthma.
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variables were calculated by BN-BMLA.
Table 5 shows the most relevant variables with high posterior 
probabilities according to the BN-BMLA analysis. As expected, 
e.g., IgE levels or inhalative allergy was highly relevant to aller-
gic asthma or eosinophil levels and allergic conjunctivitis to al-
lergic rhinitis.
In the case of genetic variations, no direct SNP-SNP or gene-
gene interactions were found. The most relevant association 
was between rs9671722 in the FRMD6 gene and exercise-in-
duced asthma with a posteriori probability of strong relevance 
of 0.99. Fig. 3 shows the most likely subgraph of the depen-
dence structure of the variables. This structure suggests a direct 
relevance of rs9671722 to exercise-induced asthma, while an-
other SNP (rs3751464) of the FRMD6 gene was found to be di-
rectly relevant to allergic rhinitis and transitively associated 
through allergic rhinitis with exercise-induced asthma.
The relationship was confirmed by logistic regression which 
showed that patients with GG genotypes of the rs9671722 SNP 
had the highest odds of having both allergic rhinitis and exer-
cise-induced asthma (OR=18.0 [5.9-54.9], P=3.7E-7; Supple-
mentary Table S3). The interaction term in the logistic regres-
sion model was significant (P=0.010).
In Supplementary Fig. S4, another graph is presented which 
shows a dendrogram of the subsets of strongly relevant vari-
ables with respect to allergic rhinitis.
 
DISCUSSION
Recent studies have shown that inflammation caused by tis-
sue damage or microbial invasion not only plays an important 
role in host defense, but also triggers regeneration and repair. It 
was also shown that house dust mite-induced asthma leads to 
a significant increase in reactive oxygen species (ROS) produc-
tion and DNA damage in lung tissues, especially in the bronchi-
al epithelium.25 However, the mechanisms, by which inflam-
mation, ROS and DNA damage stimulate regenerative respons-
Fig. 3. DAG of the most likely relations of variants and targets. The directed edges represent only probabilistic relationships between the variables which are not 
necessary causal. DAG, directed acyclic graph.
Table 5. The most relevant results of the BN-BMLA statistical method
Target variable/Variable A posteriori probability
Exercise-induced asthma/
   Non-allergic asthma 0.90
   Allergic conjunctivitis 0.78
   Allergic rhinitis 0.99
   rs9671722 (FRMD6) 0.99
Allergic asthma/
   IgE level 0.75
   Inhalative allergy 1.00
Allergic rhinitis/
   Inhalative allergy 0.88
   Allergic conjunctivitis 1.00
   Eosinophil number 1.00
Numbers show the a posteriori probability of the strong relevance of a given 
variable with respect to the target variable.
BN-BMLA, Bayesian network based Bayesian multilevel analysis of relevance; 
IgE, immunoglobulin E.
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es remain unclear.
Originally, it was found that the Hippo/YAP1 pathway played 
an important role in the regulation of organ size, but recent 
studies have indicated that YAP1 protein could also be detected 
in peripheral respiratory epithelial cells of the adult mouse 
lung.14 Furthermore, it was shown, that after depletion of club 
cells in the lungs, the distribution and intensity of YAP1 staining 
were increased. After 10 days, when the regeneration of the 
bronchiolar epithelium was complete, the YAP1 level and dis-
tribution was similar to that in the uninjured airway.14 In addi-
tion, multiple lines of evidence link the Hippo pathway to oxi-
dative stress or ROS-initiated signaling pathways and various 
pathological processes. YAP1, the major Hippo downstream 
target, also mediates ROS-triggered signaling.26 These findings 
in mice suggest that the Hippo/YAP1 pathway can also play an 
important role in the regeneration processes in human asthma.
Earlier, we carried out a partial genome screening in pediatric 
asthma and identified the FRMD6 gene which showed the 
most consistent association with asthma susceptibility and its 
role in asthma development was also confirmed in an animal 
model.15 In an independent study, we identified BIRC5, of 
which genetic variations influenced asthma susceptibility and 
expression changed significantly during asthma both in animal 
and human studies.16 As FRMD6 is a possible upstream media-
tor of the Hippo pathway and BIRC5 is a target gene of YAP1, 
these findings also indicated that the Hippo/YAP1 pathway 
might play a role in asthma.
In the present and earlier studies, we found that all the impor-
tant members of the FRMD6/Hippo/YAP1 pathway were ex-
pressed in the human induced sputum in both asthmatic pa-
tients and healthy controls. The gene expression level of differ-
ent components of the Hippo pathway correlated with diverse 
cell types. This may indicate the main sources of these mRNA 
in the sputum, suggesting that the regulation of their expres-
sions may be different in these cells and that the genes have ad-
ditional, diverse functions in these cells.
The YAP1 gene expression level was correlated with the num-
ber of sputum bronchial epithelial cells, suggesting its possible 
origin. The YAP1 mRNA level was not correlated to the severity 
of asthma or other asthma phenotypes. On Western blot, how-
ever, the protein product for YAP1 was detected only in mild 
asthmatics and was not seen in controls or in severe asthmatics.
It has been suggested that YAP1 is regulated by the Hippo 
pathway which is a kinase cascade that ends up phosphorylat-
ing and inhibiting the protein. Recently, several studies have in-
dicated that Hippo-mediated YAP1 phosphorylation is really a 
fundamental input for YAP1 regulation, but not the only one. 
Inflammation, DNA damage, and ROS or mechanical signals 
can represent separate signals with partly independent path-
ways that can regulate YAP1 phosphorylation and activity.25-29
The mechanisms of YAP1 inhibition by phosphorylation are 
nuclear exclusion, sequestration in the cytoplasm, or protea-
somal degradation. In the present study, YAP1 mRNA was de-
tected in all samples, but YAP1 protein was detected only in 
mild asthmatics. Although the detection level of the RT-PCR is 
lower than that of the Western blot, this finding is in agreement 
with the previous notion that YAP1 activity is also and perhaps 
mainly regulated on the protein level. Because of the low num-
ber of patients and the detection method, this can only be re-
garded as a preliminary finding, but based on the above-de-
scribed observations, the appearance of YAP1 in the mild asth-
matics can be explained by the asthma-associated tissue dam-
age that induces regeneration where the Hippo/YAP1 pathway 
can play an important role.30-32 Inflammation, DNA damage, 
and elevated ROS in the airway epithelium were all found to be 
associated with an increased YAP1 protein level.26 Presently, it 
cannot be explained why the YAP1 protein could not be detect-
ed in the sputum samples of severe asthmatics. However, it can 
be hypothesized that by an unknown mechanism, YAP1 is less 
or not activated in the lung of severe asthmatics which can re-
sult in a defected regeneration process in the airways which can 
contribute to irreversible organ damage and the severity of 
symptoms in these patients.
Here, we have to mention some limitations of our study. First, 
although Western blot can determine the molecular weight of 
protein and in this way has a higher specificity compared to e.g., 
enzyme-linked immunosorbent assay (ELISA), it is less sensi-
tive to and less capable of quantitative measurement. Secondly, 
in this study we did not differentiate between dephosphorylat-
ed YAP1 and phosphorylated YAP1. Also, as we have no avail-
able data on when ICS were administered, we cannot exclude 
the possibility that various time intervals between ICS adminis-
tration and sputum induction may influence our results.
The possible role of the Hippo/YAP1 pathway in asthma is 
further supported by the results that a genetic variation in the 
YAP1 gene was found to be associated with exercise-induced 
asthma and that distributions of certain haplotypes differed sig-
nificantly between different asthma GINA statuses. This latter 
observation, in line with the lack of YAP1 protein in the induced 
sputum of severe asthmatics, also supports the finding that 
haplotypes in the YAP1 gene were associated with the severity 
of the disease. It must be noted, however, that there can be dif-
ferences between childhood and adult asthma; thus, the genet-
ic associations must be confirmed in a well characterized adult 
population.
Based on our genotyping results and the characteristics of the 
asthmatic patients, we searched for the most probable interac-
tion networks with respect to different target variables. We also 
wanted to know whether there would be interactions between 
the three genes (FRMD6, YAP1, and BIRC5) whose genetic vari-
ations could be associated with asthma or asthma phenotypes 
in this population. Using the BN-BMLA method, no interaction 
was found between these genes, indicating that the genetic 
variations in the 3 genes influenced disease susceptibility inde-
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pendently from one another and that the studied population 
was too small to detect such interactions.
Within the asthma group, 2 genetic variations in the FRMD6 
gene proved to be the most relevant to exercise-induced asth-
ma and allergic rhinitis. The 2 SNPs through allergic rhinitis 
and exercise-induced asthma were in epistatic interaction with 
each other. The term exercise-induced asthma describes tran-
sient narrowing of the airways after exercise. Presently, the ex-
act mechanism of exercise-induced asthma is not known, but 
as mouth breathing is common during exercise, there is in-
creased penetration of pollutants, cold air, and allergens into 
the airways that can lead to epithelial damage, inflammation, 
and remodeling.33,34 Based on the literature and our findings, it 
is not possible to explain the relationship between the varia-
tions in the FRMD6 gene, rhinitis, and exercise-induced asth-
ma, but a possible hypothesis can be that variations in the gene 
can weaken the regeneration capacity of the Hippo pathway 
which can lead to persistent epithelial damage and asthma 
symptoms in genetically susceptible individuals.
CONCLUSION
This study provides additional evidence that the FRMD6/Hip-
po/YAP1 pathways might play a role in the pathogenesis of 
asthma and its different subtypes. Naturally, genetic associa-
tions must be confirmed in independent populations and it 
would be also interesting to reveal how exactly the activity of 
YAP1 protein is regulated in the airways of asthmatic patients. If 
additional studies can confirm that YAP1-associated pathways 
play a role in the regeneration processes in airway inflamma-
tions, these pathways can be potential novel therapeutic targets 
in asthma and other inflammatory airway diseases.
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